Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.53 |
| ▸ | CA2 | P00918 | 10/20 | 0.53 |
| ▸ | CA9 | Q16790 | 8/20 | 0.53 |
| ▸ | CA12 | O43570 | 5/20 | 0.53 |
| ▸ | CA6 | P23280 | 3/20 | 0.50 |
| ▸ | CA5A | P35218 | 3/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30593603 | 1.00 | CA1 (0.53) | CA1CA2CA9CA12CA6 | |
| Potassium SCHEMBL9493381 | 0.98 | CA1 (0.51) | CA1CA2CA9CA12CA6 | |
| SCHEMBL9493369 | 0.98 | CA1 (0.51) | CA1CA2CA9CA12CA6 | |
| SCHEMBL731096 | 0.85 | CA2 (0.48) | CA1CA2CA9CA12CA6 | |
| SCHEMBL10641489 | 0.83 | CA2 (0.47) | CA1CA2CA9CA12CA6 | |
| SCHEMBL28360228 | 0.83 | CA2 (0.52) | CA1CA2CA9CA12CA6 | |
| SCHEMBL3284628 | 0.83 | HTR2A (0.48) | CA1CA2CA9CA12CA6 | |
| SCHEMBL8428528 | 0.83 | CA2 (0.47) | CA1CA2CA9CA12CA6 | |
| SCHEMBL9379437 | 0.82 | HSD11B1 (0.54) | CA1CA2CA9CA12GABRA1 | |
| SCHEMBL5327127 | 0.82 | CA2 (0.45) | CA1CA2CA9CA12CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114728009-A | Preventing or treating diseases and disorders associated with tissue damage | 李晓祥 | 2022-07-08 | — | — | CN | claimed |
| CN-104024251-B | Benzenesulfonamide compounds and their use as therapeutic agents | 克赛农制药股份有限公司 | 2017-08-11 | — | — | CN | claimed |
| CN-105189498-B | Geminally substituted cyanoethylpyrazolopyridinones as JANUS kinase inhibitors | 默沙东公司 | 2017-06-27 | — | — | CN | claimed |
| EP-2773637-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2014-09-10 | — | — | EP | claimed |
| WO-2013064983-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-05-10 | — | — | WO | claimed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | claimed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | claimed |
| EP-1784392-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | claimed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | claimed |
| EP-1497261-A1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | claimed |
| US-6828375-B2 | Containing a thermoplastic elastomer grafted with maleic anhydride, carbon black powder, sulfonamide based material, and alkanedioic acid | HYUNDAI MOTOR COMPANY (KR) | 2004-12-07 | — | — | US | claimed |
| EP-1165866-B1 | ABRASIVE FILAMENTS OF PLASTICIZED POLYAMIDES | DU PONT (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2003091204-A1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-11-06 | — | — | WO | claimed |
| US-20020128373-A1 | Electroconductive polyamide resin composition and molded product for motor component prepared therefrom | HYUNDAI MOTOR COMPANY (KR) | 2002-09-12 | — | — | US | claimed |
| US-20250360143-A1 | COMPOSITIONS AND METHODS FOR PHARMACOLOGIC TREATMENT OF STROKE AND MYOCARDIAL ISCHEMIA REPERFUSION INJURY | UNIV CONNECTICUT (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4568948-A1 | COMPOUNDS FOR TREATING CANCER | Genesis Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024081904-A1 | METHODS FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-4009325-A | Photodegradable polyolefin composition containing an N-halo urethane | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1977-02-22 | — | — | US | disclosed |
| US-3968095-A | Photodegradable plastics containing an N-halo amide | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1976-07-06 | — | — | US | disclosed |
| US-3932352-A | POLYOLEFINS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360143-A1 | COMPOSITIONS AND METHODS FOR PHARMACOLOGIC TREATMENT OF STROKE AND MYOCARDIAL ISCHEMIA REPERFUSION INJURY | PLAT, SERPINE1, SERPINC1 | CA1 419/4885CA2 1428/4885CA9 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.